The Hospitalist Channel

Lipitor and Celebrex: Inhibition of Androgen-Independent Prostate Cancer

:57 | Hospitalist, Internal Medicine, Oncology, Oncology / Hematology

A study presented at the American Association for Cancer Research meeting showed progression of androgen-independent prostate cancer was significantly inhibited in mice by a combination of atorvastatin (Lipitor) and celecoxib (Celebrex).

For more information visit:
American Association for Cancer Research

More in Hospitalist

► 4:45

Will Current Approved Vaccines Be Effective Against Newer Coronavirus Strain?

COVID-19

In an interview for NBC News, Vin Gupta, MD, MPA, MSc, affiliate assistant professor of Health Metrics Sciences at the Institute for Health Metrics and Evaluation (IHME) at the University...

► 34:28

The Fink Tank: COVID-19 – Coronavirus Doesn’t Care Who You Voted For

COVID-19

Samuel I. Fink, MD, FACP, internal medicine specialist in private practice in Tarzana, California, and his daughter, Sarrica Fink, RN, previously in practice at Cedar Sinai Medical Center in LA,...

► 2:20

Healthcare Providers Are Not Immune to Mental Health Crises

COVID-19

Jenny C. Yip, PsyD, ABPP, shares advice for HCPs who may be struggling with anxiety or depression as a result of months of practicing medicine and managing personal and/or family...

► 34:33

The Fink Tank: COVID-19 – Do Child Care Centers Pose A Spreading Risk?

COVID-19

Samuel I. Fink, MD, FACP, internal medicine specialist in private practice in Tarzana, California, and his daughter, Sarrica Fink, RN, previously in practice at Cedar Sinai Medical Center in LA,...